HSP70-based anti-cancer immunotherapy.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Heat shock protein 70 (Hsp70) is a key cytoprotective protein.
• Hsp70 can shield cancer cells from antitumor therapies.
• Hsp70 release from cancer cells can trigger anti-tumor immune responses.

Purpose of the Study:

• To review novel data on using pure Hsp70 for glioma and melanoma therapy.
• To explore Hsp70's mechanism in activating innate and adaptive immunity against cancer.

Main Methods:

• Intratumoral delivery of pure Hsp70.
• Observation of Hsp70's effect on cancer cells and immune cells in vivo.
• Review of preclinical and early clinical trial data.

Main Results:

• Intratumoral Hsp70 penetrates cancer cells and facilitates the release of intracellular Hsp70.
• This release activates innate and adaptive immunity, leading to tumor growth inhibition.
• Preclinical and early clinical studies in pediatric brain cancer demonstrate safety and feasibility.

Conclusions:

• Intratumoral Hsp70 administration is a safe and feasible approach for treating malignancies.
• This therapy leverages Hsp70's dual role in cytoprotection and immune activation.
• Hsp70-based immunotherapy offers a novel strategy against challenging cancers like glioma and melanoma.